📊 APHD Key Takeaways
Is Verde Bio Holdings, Inc.. (APHD) a Good Investment?
Verde Bio Holdings is in severe financial distress with collapsing revenues ($2.3K), massive operating losses (-$1.0M), and critically weak liquidity (0.06x current ratio). The company is burning cash (-$943.2K operating cash flow) with minimal equity cushion ($119.0K) and near-zero available capital, indicating imminent solvency risk.
Verde Bio Holdings shows severely deteriorated fundamentals: revenue has effectively collapsed, margins are deeply negative, and the company is generating large operating and net losses against a very small revenue base. Financial health is weak, with minimal cash, a current ratio of 0.06x, negative operating cash flow, and only a thin equity cushion, which raises substantial going-concern and dilution risk.
Why Buy Verde Bio Holdings, Inc.. Stock? APHD Key Strengths
- No long-term debt obligations reducing refinancing risk
- Positive stockholders equity remaining ($119.0K) though minimal
- Data available for analysis with 28 metrics reported
- Total assets still exceed total liabilities
- No long-term debt reduces balance-sheet leverage risk
- Capital expenditure needs appear minimal in the latest period
APHD Stock Risks: Verde Bio Holdings, Inc.. Investment Risks
- Revenue collapse of 100% YoY indicating business failure or operational shutdown
- Critically low current ratio of 0.06x with insufficient liquid assets to cover liabilities
- Negative cash flow generation (-$943.2K) unsustainable with only $11.6K cash on hand
- Extreme negative margins (operating margin -44,880%, net margin -92,359%) indicating operational non-viability
- Minimal equity base ($119.0K) provides negligible buffer for continued losses
- No insider activity in 90 days suggesting potential abandonment or distress
- Revenue deterioration is extreme, indicating poor business viability and weak growth quality
- Liquidity is critically weak with very low cash and a 0.06x current ratio
- Persistent losses and negative free cash flow threaten solvency and may force external financing
Key Metrics to Watch
- Quarterly revenue trends and operational status
- Cash position depletion rate and runway remaining
- Quarterly operating cash flow and path to profitability or restructuring
- Changes in liabilities and covenant violations
- Any material events, bankruptcy filings, or going concern disclosures
- Cash balance relative to near-term liabilities and operating cash burn
- Revenue recovery and reduction in operating losses
Verde Bio Holdings, Inc.. (APHD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
APHD Profit Margin, ROE & Profitability Analysis
APHD vs Energy Sector: How Verde Bio Holdings, Inc.. Compares
How Verde Bio Holdings, Inc.. compares to Energy sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Verde Bio Holdings, Inc.. Stock Overvalued? APHD Valuation Analysis 2026
Based on fundamental analysis, Verde Bio Holdings, Inc.. has mixed fundamental signals relative to the Energy sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Verde Bio Holdings, Inc.. Balance Sheet: APHD Debt, Cash & Liquidity
APHD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Verde Bio Holdings, Inc..'s revenue has grown significantly by 8,529% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.53 indicates the company is currently unprofitable.
APHD Revenue Growth, EPS Growth & YoY Performance
APHD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | N/A | -$4.3K | $0.00 |
| Q3 2019 | N/A | -$81.0K | $0.00 |
| Q2 2019 | N/A | -$122.4K | $0.00 |
| Q1 2019 | N/A | -$84.5K | $0.00 |
| Q3 2018 | $14.0K | -$12.9K | N/A |
| Q2 2018 | $16.8K | -$309.2K | N/A |
| Q1 2018 | $11.1K | -$84.5K | N/A |
| Q3 2017 | $22.5K | -$12.9K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Verde Bio Holdings, Inc.. Dividends, Buybacks & Capital Allocation
APHD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Verde Bio Holdings, Inc.. (CIK: 0001490054)
📋 Recent SEC Filings
❓ Frequently Asked Questions about APHD
What is the AI rating for APHD?
Verde Bio Holdings, Inc.. (APHD) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are APHD's key strengths?
Claude: No long-term debt obligations reducing refinancing risk. Positive stockholders equity remaining ($119.0K) though minimal. ChatGPT: Total assets still exceed total liabilities. No long-term debt reduces balance-sheet leverage risk.
What are the risks of investing in APHD?
Claude: Revenue collapse of 100% YoY indicating business failure or operational shutdown. Critically low current ratio of 0.06x with insufficient liquid assets to cover liabilities. ChatGPT: Revenue deterioration is extreme, indicating poor business viability and weak growth quality. Liquidity is critically weak with very low cash and a 0.06x current ratio.
What is APHD's revenue and growth?
Verde Bio Holdings, Inc.. reported revenue of $2.3K.
Does APHD pay dividends?
Verde Bio Holdings, Inc.. does not currently pay dividends.
Where can I find APHD SEC filings?
Official SEC filings for Verde Bio Holdings, Inc.. (CIK: 0001490054) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is APHD's EPS?
Verde Bio Holdings, Inc.. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is APHD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Verde Bio Holdings, Inc.. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is APHD stock overvalued or undervalued?
Valuation metrics for APHD: ROE of -1,799.6% (sector avg: 14%), net margin of -92,358.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy APHD stock in 2026?
Our dual AI analysis gives Verde Bio Holdings, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is APHD's free cash flow?
Verde Bio Holdings, Inc..'s operating cash flow is $-943.2K, with capital expenditures of $0.0. FCF margin is -40,673.1%.
How does APHD compare to other Energy stocks?
Vs Energy sector averages: Net margin -92,358.8% (avg: 12%), ROE -1,799.6% (avg: 14%), current ratio 0.06 (avg: 1.3).